CA3014538A1 - Molecular design of recombinant protein drug - Google Patents
Molecular design of recombinant protein drug Download PDFInfo
- Publication number
- CA3014538A1 CA3014538A1 CA3014538A CA3014538A CA3014538A1 CA 3014538 A1 CA3014538 A1 CA 3014538A1 CA 3014538 A CA3014538 A CA 3014538A CA 3014538 A CA3014538 A CA 3014538A CA 3014538 A1 CA3014538 A1 CA 3014538A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- mutant
- motif
- amino acid
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title description 3
- 238000013461 design Methods 0.000 title description 2
- 230000000694 effects Effects 0.000 claims abstract description 139
- 108091006112 ATPases Proteins 0.000 claims abstract description 74
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims abstract description 74
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims abstract description 24
- 108010079505 Endostatins Proteins 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- 230000033115 angiogenesis Effects 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 30
- 230000035772 mutation Effects 0.000 claims description 27
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 11
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 230000003527 anti-angiogenesis Effects 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 8
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 208000004930 Fatty Liver Diseases 0.000 claims description 7
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 7
- 206010022489 Insulin Resistance Diseases 0.000 claims description 7
- 208000010706 fatty liver disease Diseases 0.000 claims description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 238000010353 genetic engineering Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 101500026378 Homo sapiens Endostatin Proteins 0.000 claims description 3
- 238000013459 approach Methods 0.000 claims description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- -1 aromatic amino acid Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 36
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 42
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 42
- 230000010595 endothelial cell migration Effects 0.000 description 33
- 241000588722 Escherichia Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 18
- 210000002889 endothelial cell Anatomy 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 230000005012 migration Effects 0.000 description 12
- 238000013508 migration Methods 0.000 description 12
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 101100294701 Arabidopsis thaliana NSN1 gene Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 4
- 102000008300 Mutant Proteins Human genes 0.000 description 4
- 108010021466 Mutant Proteins Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000869 mutational effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 102220005537 rs33984621 Human genes 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 230000006682 Warburg effect Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000012501 chromatography medium Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 101001047088 Canis lupus familiaris Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000006452 cellular component assembly Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510079486 | 2015-02-13 | ||
| CN201510079486.7 | 2015-02-13 | ||
| CN201510736184 | 2015-11-02 | ||
| CN201510736184.2 | 2015-11-02 | ||
| PCT/CN2016/073773 WO2016127948A1 (zh) | 2015-02-13 | 2016-02-14 | 一种重组蛋白质药物的分子设计 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3014538A1 true CA3014538A1 (en) | 2016-08-18 |
Family
ID=56614147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3014538A Pending CA3014538A1 (en) | 2015-02-13 | 2016-02-14 | Molecular design of recombinant protein drug |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10869910B2 (enExample) |
| EP (1) | EP3269731B1 (enExample) |
| JP (1) | JP6896636B2 (enExample) |
| CN (2) | CN114249816B (enExample) |
| AU (2) | AU2016218635B2 (enExample) |
| CA (1) | CA3014538A1 (enExample) |
| DK (1) | DK3269731T5 (enExample) |
| WO (1) | WO2016127948A1 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890155B (zh) * | 2010-05-25 | 2012-07-25 | 江苏先声药物研究有限公司 | 一种药物组合物及其应用 |
| WO2013034116A1 (zh) * | 2011-09-09 | 2013-03-14 | 清华大学 | 对atp结合位点进行突变的血管内皮抑制素突变体 |
| CN107148277B (zh) * | 2014-11-03 | 2022-03-22 | 清华大学 | 一种抑制脂肪细胞分化和胰岛素耐受的药物 |
-
2016
- 2016-02-14 CN CN202111201002.3A patent/CN114249816B/zh active Active
- 2016-02-14 EP EP16748749.5A patent/EP3269731B1/en active Active
- 2016-02-14 US US15/550,751 patent/US10869910B2/en active Active
- 2016-02-14 CN CN201680010044.XA patent/CN107428809B/zh active Active
- 2016-02-14 DK DK16748749.5T patent/DK3269731T5/da active
- 2016-02-14 CA CA3014538A patent/CA3014538A1/en active Pending
- 2016-02-14 AU AU2016218635A patent/AU2016218635B2/en active Active
- 2016-02-14 JP JP2017542389A patent/JP6896636B2/ja active Active
- 2016-02-14 WO PCT/CN2016/073773 patent/WO2016127948A1/zh not_active Ceased
-
2020
- 2020-09-28 US US17/035,497 patent/US20210085754A1/en active Pending
- 2020-10-13 AU AU2020256316A patent/AU2020256316B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3269731A4 (en) | 2018-08-15 |
| JP6896636B2 (ja) | 2021-06-30 |
| EP3269731B1 (en) | 2023-10-04 |
| AU2020256316A1 (en) | 2020-11-12 |
| AU2016218635A1 (en) | 2017-10-05 |
| CN114249816A (zh) | 2022-03-29 |
| CN114249816B (zh) | 2024-09-06 |
| CN107428809A (zh) | 2017-12-01 |
| WO2016127948A1 (zh) | 2016-08-18 |
| US20180200337A1 (en) | 2018-07-19 |
| US20210085754A1 (en) | 2021-03-25 |
| JP2018507854A (ja) | 2018-03-22 |
| AU2016218635B2 (en) | 2020-07-23 |
| DK3269731T5 (da) | 2024-10-14 |
| AU2020256316B2 (en) | 2021-10-07 |
| US10869910B2 (en) | 2020-12-22 |
| DK3269731T3 (da) | 2023-10-30 |
| EP3269731A1 (en) | 2018-01-17 |
| CN107428809B (zh) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2964761B1 (en) | Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment | |
| JPH01501283A (ja) | 新規な型のコロニー刺激因子―１ | |
| JP7729842B2 (ja) | ｒｈＦＧＦ２１融合タンパク質、ｒｈＦＧＦ２１融合タンパク質をコードするポリヌクレオチド、ｒｈＦＧＦ２１融合タンパク質を含有する組成物、及びｒｈＦＧＦ２１融合タンパク質の使用 | |
| CN104650210A (zh) | 作为体内造血刺激剂的tat-hoxb4h重组蛋白质的制备方法 | |
| US20180163214A1 (en) | Slit2d2-hsa fusion protein and use thereof against tumours | |
| US7078485B2 (en) | N-terminal modified recombinant human endostatin and its production | |
| CN114796525B (zh) | 细胞周期调控蛋白抑制剂在肿瘤治疗中的应用 | |
| WO2010120931A2 (en) | E2f as a target for treatment of hormone refractory prostate cancer | |
| AU2020256316B2 (en) | Molecular design of recombinant protein drug | |
| CN106432483B (zh) | 沼水蛙皮肤丝氨酸蛋白酶抑制肽及其基因和制药应用 | |
| US20220211624A1 (en) | Fusion protein nanodisk compositions and methods of treatment | |
| RU2285537C1 (ru) | Противоопухолевый пептидный препарат на основе фрагмента альфа-фетопротеина, его конъюгат, фармацевтическая композиция и способ лечения гормонзависимых опухолей | |
| WO2023169125A1 (zh) | mTORC2抑制剂 | |
| JPH03297388A (ja) | 新規なｔｎｆ変異体、その製造法及びそれを有効成分とする抗腫瘍剤 | |
| HK1240943B (zh) | 一种重组蛋白质药物的分子设计 | |
| JP2548204B2 (ja) | 新生理活性ポリペプチド | |
| HK1240943A1 (en) | Molecular design of recombinant protein drug | |
| WO2004091650A1 (fr) | Utilisation de la troponine i cardiaque pour preparer des medicaments antitumoraux | |
| JP5422832B2 (ja) | 不活化遺伝子再活性化ペプチド | |
| CN102212126B (zh) | 具有抑制内皮细胞生长活性的重组EDI-8t蛋白 | |
| WO2010095422A1 (ja) | 悪性腫瘍治療剤 | |
| JPS63270697A (ja) | ヒト腫瘍壊死因子関連蛋白質 | |
| JPH02156884A (ja) | ポリペプチド及びその製造方法 | |
| JPS62185097A (ja) | インタ−ロイキン１活性を示すポリペプチド | |
| JPS63188396A (ja) | 新規生理活性ポリペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210202 |
|
| EEER | Examination request |
Effective date: 20210202 |
|
| EEER | Examination request |
Effective date: 20210202 |
|
| EEER | Examination request |
Effective date: 20210202 |
|
| EEER | Examination request |
Effective date: 20210202 |
|
| EEER | Examination request |
Effective date: 20210202 |
|
| EEER | Examination request |
Effective date: 20210202 |